If future trials continue to show positive results, zilebesiran could become an important new option for treating high blood pressure. A treatment that works for months at a time could help more ...

This injection reduces the production of angiotensin, a hormone that increases blood pressure, in the body.

A new Lancet review highlights innovative hypertension treatments, including twice-yearly injections that may offer long-lasting blood pressure control.

LONDON — Nearly half of Americans with high blood pressure struggle to control it, even while taking medication every day. But a groundbreaking new drug called zilebesiran has shown that just one ...

A new Lancet review suggests that just two injections a year could transform hypertension treatment, offering a long acting and potentially more effective approach to managing high blood pressure.

The development, researchers say, could fundamentally change how hypertension is managed, particularly at a time when control rates remain alarmingly low.

The global trial, KARDIA-2, involved 663 people with high blood pressure whose condition wasn’t being well managed with their standard treatment. In the trial, patients were given an injection of a ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

The way high blood pressure is treated could soon witness its biggest shift in decades, with long-acting injectable therapies promising control with just two doses a year instead of daily pills. A ...

Women with metastatic breast cancer often face multiple chronic conditions, and high blood pressure is among the most common.